关于

关于

Catenion作为一家管理咨询公司,一直致力于协助制药及医疗产品公司创建更新型更有效的战略和组织。

基于对行业趋势和公司动态的深刻理解,我们可以帮助客户制定切实可行的竞争战略。 此外,我们帮助客户营造一个良好的组织氛围,促进创造力和医学突破,来解决制药创新方面的文化障碍。 同时,在客户评估其项目和产品组合的价值以及风险时,我们能够协助他们改进评估方式以及资源分配方式。

为了提高组织绩效,我们与客户单位的董事会、首席执行官、业务部门总经理、研发、财务、战略、投资组合管理及业务发展方面的主管和其他高管携手合作。 我们具备以下三项差异化优势,让我们能够成功做好这一工作:

以科学为驱动因素的战略

我们专注于科学驱动战略:我们拥有一支由生命科学博士组成的团队,通过全方位多层面的评估,为您解答关键问题。

丰富的经验与深厚的关系

我们在全球生物制药行业有着二十多年的丰富经验和深厚关系。

数据科学

我们拥有一支由生物信息学家、计算生物学家和数据工程师组成的团队,将数据科学融入我们的分析之中。

我们同样热衷于帮助我们的客户推动创新,从而为医学进步做出贡献。 我们不断寻求能够发挥核心能力的相关创业机会,并愿意为之承担风险。

我们的价值

我们公司始终且将继续坚守如下诸项原则:

因此,我们总是会付出超出客户期望值的努力,不断完善和重塑我们的探索方式及分析方法。与自我推销相比,为客户提供更优质的服务才是我们擅长的领域。
Catenion的合伙人和咨询顾问在这里工作,只是因为他们热爱所做的工作 — 而不是为了借此拼凑一份简历,让在这里的工作经验成为通往职业荣耀之路的垫脚石。

我们的团队

Markus Thunecke博士

高级合伙人

Matthias Krings博士

高级合伙人

Arno Heuermann

COO,合伙人/总经理

Christian Elze

高级合伙人

Pascal Joly博士

投资总监

Mariana Cerdeira博士

经理

Ana Rita da Costa博士

经理

Simin Oz博士

经理/数据科学家

Damir Omerbasic博士

经理

Andrea lseppon博士

咨询顾问

Erika Kuchen博士

咨询顾问/数据科学家

Tahere Kalantary博士

咨询顾问/数据科学家

Mayur Vadhvani博士

咨询顾问

Bea Kaufmann博士

咨询顾问

Ilkin Ozer博士

咨询顾问

Alexander Wallroth博士

咨询顾问

Duc Vu

咨询顾问

Haydar Demirdizen

资深数据工程师

Christopher Buccitelli博士

咨询顾问/数据科学家

Lina Zarate博士

分析师

Marija Liutkute博士

分析师

David Puga博士

分析师

Pascal Stehling

数据工程师

Charles Malek博士

分析师

Saren Tasciyan博士

分析师/数据科学家

Yu-Wen Hsieh謝郁文博士

分析师

Giulia Caglio博士

分析师/数据科学家

Jie-Ming (Jamie) Lin

分析师

Shilpashree Mallesh博士

分析师

Priyankaa Pitcheshwar博士

分析师

Linda Schermeier

研究员

即将公布

分析师

Bettina Eyermann

行政经理

Deborah Frick

财务经理

Katarina Ebert

人力资源(HR)经理

道德准则

在Catenion,诚信、道德和透明度至关重要。 我们很自豪地向客户、供应商和我们的团队分享我们的道德准则。
Catenion Markus Thunecke compressed

Dr. Markus Thunecke

Markus has written several Catenion Commentaries including “Risk Profiles of Corporate Portfolio Strategies” as well as “Elements of Winning Strategies in R&D”, “Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations”, “Recombinant Portfolio Management – Recognising and Enabling Innovation”. He also co–authored “Zero Base R&D” and “The Challenge for Japan’s Pharmaceutical Top Twenty”. All of them are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Markus Thunecke is a founding Senior Partner of Catenion who lives in Berlin, Germany. Markus started his consulting career in 1997 at Mercer Management Consulting before joining a strategy consulting boutique, Theron, and setting up Catenion in 2003.

Markus has helped numerous clients around the globe in the pharmaceutical and medical products industries create competitive advantage. In addition to his work on strategy, Markus specialises in developing leading–edge analytical tools and combining them with organisational development capabilities. Markus is the developer of a number of Catenion’s proprietary tools for portfolio management and risk assessment. In recent engagements, Markus has helped clients develop and realign their R&D strategies, review their discovery and development portfolios, and create organisational models that foster innovation.

Markus is a frequent speaker at conferences on R&D strategy and portfolio management.

He holds a PhD in biochemistry from the University of Heidelberg, where he generated transgenic animal models for Alzheimer’s disease. He also has three years of research experience within the CNS field at Schering AG.

Catenion Matthias Krings

Dr. Matthias Krings

Matthias Krings is a founding Partner of Catenion.

He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also resposible for the creation and delivery of bespoke client education programs in the Catenion Academy.

Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.

Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution (Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans).

Matthias lives in Munich & Berlin. He enjoys cooking, gardening, watersports and traveling.

Matthias co-authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management – Recognizing and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Catenion Arno Heuermann 2

Arno Heuermann

Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.

While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.

In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.

In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.

Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.

He is experienced in the diverse practices of patent management and has made numerous successful inventions.

Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.

Catenion Christian Elze

Christian Elze

Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.

Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.

Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement,  Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.

Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and lives with his family in London.